Top Advances of the Year: Pancreatic Cancer

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2023 Sep 30

PMID 37776536

Authors

Emilie A K Warren

Gregory B Lesinski

Shishir K Maithel

Affiliations

Soon will be listed here.

Citing Articles

Case report: A successful case of targeted immunotherapy for locally advanced pancreatic cancer under non-surgical conditions.

Bi Y, Yv H, Ma X, Chen S Front Immunol. 2025; 15:1519186.

PMID: 39867905 PMC: 11760604. DOI: 10.3389/fimmu.2024.1519186.

Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population.

Sini M, Doro M, Frogheri L, Zinellu A, Paliogiannis P, Porcu A J Transl Med. 2024; 22(1):108.

PMID: 38280995 PMC: 10821545. DOI: 10.1186/s12967-024-04923-3.

References

Nwosu Z, Ward M, Sajjakulnukit P, Poudel P, Ragulan C, Kasperek S . Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Nature. 2023; 618(7963):151-158. PMC: 10232363. DOI: 10.1038/s41586-023-06073-w. View

Kang Y, Deng J, Ling J, Li X, Chiang Y, Koay E . 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest. 2022; 132(24). PMC: 9753992. DOI: 10.1172/JCI151604. View

Bekaii-Saab T, Yaeger R, Spira A, Pelster M, Sabari J, Hafez N . Adagrasib in Advanced Solid Tumors Harboring a Mutation. J Clin Oncol. 2023; 41(25):4097-4106. PMC: 10852394. DOI: 10.1200/JCO.23.00434. View

Garcia Garcia C, Huang Y, Fuentes N, Turner M, Monberg M, Lin D . Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Gastroenterology. 2022; 162(7):2018-2031. PMC: 9278556. DOI: 10.1053/j.gastro.2022.02.024. View

Dias Costa A, Vayrynen S, Chawla A, Zhang J, Vayrynen J, Lau M . Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Clin Cancer Res. 2022; 28(23):5167-5179. PMC: 9999119. DOI: 10.1158/1078-0432.CCR-22-1125. View

McAndrews K, Chen Y, Darpolor J, Zheng X, Yang S, Carstens J . Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. Cancer Discov. 2022; 12(6):1580-1597. PMC: 9399904. DOI: 10.1158/2159-8290.CD-20-1484. View

Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J . Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022; 23(10):1261-1273. PMC: 11702314. DOI: 10.1016/S1470-2045(22)00541-1. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Somani V, Zhang D, Dodhiawala P, Lander V, Liu X, Kang L . IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2022; 162(7):2047-2062. PMC: 9387774. DOI: 10.1053/j.gastro.2022.02.035. View

10.

Rojas L, Sethna Z, Soares K, Olcese C, Pang N, Patterson E . Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023; 618(7963):144-150. PMC: 10171177. DOI: 10.1038/s41586-023-06063-y. View

11.

Dixit A, Sarver A, Zettervall J, Huang H, Zheng K, Brekken R . Targeting TNF-α-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling. JCI Insight. 2022; 7(22). PMC: 9746819. DOI: 10.1172/jci.insight.153242. View

12.

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

13.

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

14.

Maddipati R, Norgard R, Baslan T, Rathi K, Zhang A, Saeid A . Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Cancer Discov. 2021; 12(2):542-561. PMC: 8831468. DOI: 10.1158/2159-8290.CD-20-1826. View

15.

Chia L, Wang B, Kim J, Luo L, Shuai S, Herrera I . HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation. J Clin Invest. 2023; 133(6). PMC: 10014113. DOI: 10.1172/JCI151601. View

16.

Demyan L, Habowski A, Plenker D, King D, Standring O, Tsang C . Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Ann Surg. 2022; 276(3):450-462. PMC: 10202108. DOI: 10.1097/SLA.0000000000005558. View

17.

Chen Y, Yang S, Tavormina J, Tampe D, Zeisberg M, Wang H . Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell. 2022; 40(8):818-834.e9. PMC: 9831277. DOI: 10.1016/j.ccell.2022.06.011. View

18.

Labori K, Bratlie S, Andersson B, Angelsen J, Biorserud C, Bjornsson B . Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024; 9(3):205-217. DOI: 10.1016/S2468-1253(23)00405-3. View

19.

Katz M, Shi Q, Meyers J, Herman J, Chuong M, Wolpin B . Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022; 8(9):1263-1270. PMC: 9284408. DOI: 10.1001/jamaoncol.2022.2319. View

20.

Mirlekar B, Wang Y, Li S, Zhou M, Entwistle S, De Buysscher T . Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep Med. 2022; 3(9):100744. PMC: 9512696. DOI: 10.1016/j.xcrm.2022.100744. View